Reading time: three minutes
Hormone replacement therapy has long been associated with safety concerns, largely due to warnings introduced decades ago. Recent updates from the FDA have changed how these risks are communicated, prompting renewed discussion around HRT safety and appropriate use.
Why Was Hormone Replacement Therapy Considered Risky?
HRT was considered risky because early large-scale studies linked certain hormone treatments to higher rates of cardiovascular events, blood clots, and some cancers.
These findings came from studies published in the early 2000s that examined postmenopausal women using hormone formulations, doses, and delivery methods common at the time.
As a result, hormone therapy use declined, and many patients were advised to discontinue or avoid treatment.
What Was the FDA Black Box Warning on HRT?
A black box warning is the strongest safety warning the FDA requires. It is used to highlight serious or potentially life-threatening risks associated with a medication.
In response to those early study findings, the FDA applied a black box warning to HRT related to health risks associated with certain estrogen and progestin combinations.
This labeling influenced how hormone therapy was prescribed and how patients viewed it, often leading to avoidance even in cases where individualized assessment may have supported its use.
Why Did the FDA Remove the Black Box Warning?
The FDA removed the black box warning after evidence showed that hormone therapy does not carry the same level of risk for all patients.
Several findings drove this decision:
- Timing mattered: Many early studies included women who started hormone therapy long after menopause, when baseline cardiovascular risk was already higher.
- Formulations differed: Older studies relied on higher-dose formulations that are less commonly used today.
- Delivery method mattered: Oral hormones were studied more extensively than hormones delivered through the skin, sublingually, or applied locally.
- Broad warnings lacked precision: Applying the same warning to all patients and therapies no longer reflected the evidence.
The FDA concluded that a single, blanket warning did not accurately represent how hormone therapy is used or evaluated today.
What the FDA’s Decision Does and Does Not Mean
The removal of the black box warning does not mean hormone replacement therapy is risk-free or appropriate for every patient. Instead, it reflects a clearer understanding that risk varies from person to person.
Safety depends on personal health history, timing, and how therapy is prescribed and monitored. Individual evaluation is essential, and treatment decisions should be made on a case-by-case basis.
How HRT Safety Is Evaluated Today
Modern HRT safety is assessed on an individual basis rather than through broad risk categories. Evaluation focuses on the patient’s health profile and how the therapy is prescribed.
Key considerations include:
- Formulation: Different estrogens and progestogens interact with the body in different ways.
- Delivery method: Oral, transdermal, sublingual, and localized therapies affect metabolism and risk differently.
- Dose: Lower, physiologic dosing is more common than in earlier decades.
- Timing: Starting therapy closer to menopause carries different considerations than initiating treatment years later.
Many current approaches include bioidentical hormone therapy (BHRT), which uses hormones chemically identical to those produced by the body. BHRT is commonly prescribed within individualized care and evaluated using the same safety considerations as other hormone therapies.
Candidates for Hormone Replacement Therapy
Candidacy for hormone replacement therapy depends on individual circumstances rather than age alone. Some people may benefit from HRT, while others may not be suitable candidates.
Evaluation typically considers:
- Severity and impact of symptoms
- Personal and family medical history
- Cardiovascular and cancer risk factors
- Time since menopause or hormonal change
- Individual goals and preferences
The decision to use hormone therapy involves weighing potential benefits against known risks through individualized evaluation.
Schedule a Consultation
If you are considering hormone replacement therapy or have questions about its safety, an individualized evaluation can help determine whether it is appropriate for your health goals.
At Pure Body Health, care is led by naturopathic providers who assess hormone therapy within the context of your overall health, history, and current evidence.
To book an appointment at our wellness clinic in Tempe, call (480) 427-0442 or complete the online inquiry form. Visit us at 1553 W Todd Drive, Suite 106, Tempe, AZ.
FAQs
Age and time since menopause influence how the body responds to hormone therapy. Risks and benefits vary depending on when treatment begins. Generally, the goal is to achieve optimal healthy hormone levels based on the individual’s age and sex; this in turn can often minimize risks that could occur with hormone levels that are too high or too low.
Some hormone therapies can slightly increase the risk of some cancers depending on formulation, duration, and individual factors. Risk assessment is part of the evaluation process.
Hormone therapy is generally approached with caution in individuals with a history of breast cancer and requires careful evaluation and coordination with appropriate providers.